• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CARGO Therapeutics Inc.

    3/12/25 5:01:06 PM ET
    $CRGX
    Get the next $CRGX alert in real time by email
    S-8 1 d926284ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 12, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    CARGO Therapeutics, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   84-4080422

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    835 Industrial Road, Suite 400

    San Carlos, California

      94070
    (Address of Principal Executive Offices)   (Zip Code)

     

     

    CARGO Therapeutics, Inc. 2023 Incentive Award Plan

    (Full Title of the Plan)

     

     

    Gina Chapman

    Chief Executive Officer

    CARGO Therapeutics, Inc.

    1900 Alameda De Las Pulgas, Suite 350

    San Mateo, California

    (650) 379-6143

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    B. Shayne Kennedy

    Benjamin A. Potter

    J. Ross McAloon

    Latham & Watkins LLP

    140 Scott Drive

    Menlo Park, California 94025

    (650) 328-4600

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    In this registration statement, CARGO Therapeutics, Inc. is sometimes referred to as “Registrant,” “we,” “us” or “our.”

    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8

    This Registration Statement on Form S-8 is filed by the Registrant, relating to 2,302,126 shares of its common stock, $0.001 par value (the “Common Stock”), issuable to eligible employees, directors and consultants of the Registrant under the Registrant’s 2023 Incentive Award Plan (the “2023 Plan”). Shares available for issuance under the 2023 Plan were previously registered on registration statements on Form S-8 filed with the SEC on November 14, 2023 (File No.  333-275556) and March 22, 2024 (File No.  333-278160) (collectively, the “Prior Registration Statements”). The Prior Registration Statements are currently effective. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with Section E of the General Instructions to Form S-8 regarding Registration of Additional Securities. Pursuant to Section E of the General Instructions to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    Item 3. Incorporation of Documents by Reference.

    The SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this registration statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this registration statement the following documents previously filed with the SEC:

     

      (a)

    The contents of the Registrant’s earlier Registration Statements on Form S-8 relating to the 2023 Plan, previously filed with the SEC on November 14, 2023 (File No. 333-275556) and March 22, 2024 (File No. 333-278160);

     

      (b)

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 12, 2025;

     

      (c)

    the Registrant’s Current Report on Form 8-K filed with the SEC on January  29, 2025; and

     

      (d)

    the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A, filed with the SEC on November 7, 2023, and any amendment or report filed with the SEC for the purpose of updating the description, including Exhibit 4.1 to the Annual Report on Form 10-K for the year ended December 31, 2024.

     

    1


    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the registration statement which indicates that all of the shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of the filing of such documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this registration statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

    2


    Item 8. Exhibits.

     

    Exhibit

    Number

     

    Exhibit Description

       Incorporated by Reference  

    Filed

    Herewith

     
      

    Form

       Date    Number  

     

     
    4.1   Amended and Restated Certificate of Incorporation, as amended, currently in effect    8-K    11/14/2023    3.1  
    4.2   Bylaws, as amended, currently in effect    8-K    11/14/2023    3.2  
    4.3   Form of Common Stock Certificate    S-1/A    11/6/2023    4.2  
    5.1   Opinion of Latham & Watkins LLP              X  
    23.1   Consent of Latham & Watkins LLP (included in Exhibit 5.1)              X  
    23.2   Consent of independent registered public accounting firm              X  
    24.1   Power of Attorney. Reference is made to the signature page to the Registration Statement              X  
    99.1(a)#   2023 Incentive Award Plan    S-8    11/14/2023    99.2(a)#  
    99.1(b)#   Form of Stock Option Grant Notice and Stock Option Agreement under the 2023 Incentive Award Plan    S-8    11/14/2023    99.2(b)#  
    99.1(c)#   Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2023 Incentive Award Plan    S-8    11/14/2023    99.2(c)#  
    107   Filing Fee Table              X  

     

    #

    Indicates management contract or compensatory plan.

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Carlos, State of California, on the 12th day of March, 2025.

     

    CARGO Therapeutics, Inc.

    By:

     

    /s/ Gina Chapman

      Name:   Gina Chapman
      Title:   Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Gina Chapman and Anup Radhakrishnan, and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Gina Chapman

    Gina Chapman

       Chief Executive Officer and Director (principal executive officer)   March 12, 2025

    /s/ Anup Radhakrishnan

    Anup Radhakrishnan

       Chief Financial Officer and Chief Operating Officer (principal financial officer and principal accounting officer)   March 12, 2025

    /s/ John Orwin

    John Orwin

       Director   March 12, 2025

    /s/ Abraham Bassan

    Abraham Bassan

       Director   March 12, 2025

    /s/ Reid Huber

    Reid Huber

       Director   March 12, 2025

    /s/ David Lubner

    David Lubner

       Director   March 12, 2025

    /s/ Krishnan Viswanadhan

    Krishnan Viswanadhan

       Director   March 12, 2025


    Signature

      

    Title

     

    Date

    /s/ Kapil Dhingra

    Kapil Dhingra

       Director   March 12, 2025

    /s/ Jane Pritchett Henderson

    Jane Pritchett Henderson

       Director   March 12, 2025
    Get the next $CRGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRGX

    DatePrice TargetRatingAnalyst
    1/30/2025Buy → Neutral
    Chardan Capital Markets
    1/30/2025$32.00 → $3.00Buy → Hold
    Jefferies
    1/30/2025$34.00 → $4.00Overweight → Neutral
    Piper Sandler
    1/30/2025Outperform → Mkt Perform
    William Blair
    1/30/2025Overweight → Underweight
    Analyst
    1/30/2025$32.00 → $7.00Buy → Hold
    Truist
    1/30/2025Buy → Neutral
    H.C. Wainwright
    11/26/2024Outperform
    William Blair
    More analyst ratings

    $CRGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CARGO Therapeutics Provides Corporate Update

      - Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 - - Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination - SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX) today provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1, a Phase 2 study of firicabtagene autoleucel (firi-cel). The Company's Board of Directors has made the decis

      3/18/25 4:05:00 PM ET
      $CRGX
    • CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options

      CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.CARGO to implement a workforce reduction of approximately 50%.Phase 1 dose escalation study enrollment for CRG-023 on track to initiate in Q2 2025. SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients, today announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBC

      1/29/25 4:05:00 PM ET
      $CRGX
    • CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025

      - 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023, CARGO's tri-specific CAR T, cleared by the FDA; Phase 1 study enrollment expected to initiate mid-year 2025 - - CARGO announces novel allogeneic platform based on a universal allogeneic-enabling vector intended to be paired with any new or existing CAR vector to create an allogeneic CAR T-cell therapy while leveraging existing autologous drug product processes -    SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage bi

      1/10/25 8:00:00 AM ET
      $CRGX

    $CRGX
    Leadership Updates

    Live Leadership Updates

    See more
    • CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      - 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 - - CRG-023 pre-clinical data to be presented at ASH 2024; IND submission anticipated Q1'25 with Phase 1 initiation planned for 2025 - - Anup Radhakrishnan, CFO of CARGO Therapeutics, appointed as COO and CFO - SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided a

      11/12/24 4:05:00 PM ET
      $CRGX
    • CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

      – Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Jane Pritchett Henderson to its Board of Directors. Ms. Henderson will also serve as a member of the audit and compensation committees. "Jane's appointment exemplifies CARGO's ongoing commitment to strong corporate g

      6/4/24 4:05:00 PM ET
      $CRGX
    • CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

      - 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) --  CARGO Therapeutics, Inc. (NASDAQ

      5/14/24 4:05:00 PM ET
      $CRGX

    $CRGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Samsara Biocapital Gp, Llc bought $4,998,000 worth of shares (294,000 units at $17.00) (SEC Form 4)

      4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)

      6/3/24 9:45:28 PM ET
      $CRGX

    $CRGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CARGO Therapeutics downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded CARGO Therapeutics from Buy to Neutral

      1/30/25 7:52:27 AM ET
      $CRGX
    • CARGO Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded CARGO Therapeutics from Buy to Hold and set a new price target of $3.00 from $32.00 previously

      1/30/25 7:51:56 AM ET
      $CRGX
    • CARGO Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded CARGO Therapeutics from Overweight to Neutral and set a new price target of $4.00 from $34.00 previously

      1/30/25 7:51:20 AM ET
      $CRGX

    $CRGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Radhakrishnan Anup sold $6,522 worth of shares (1,629 units at $4.00), decreasing direct ownership by 2% to 77,317 units (SEC Form 4)

      4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)

      4/8/25 5:04:23 PM ET
      $CRGX
    • Officer Radhakrishnan Anup was granted 72,500 shares, increasing direct ownership by 1,125% to 78,946 units (SEC Form 4)

      4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)

      3/18/25 4:17:25 PM ET
      $CRGX
    • Chief Medical Officer Laport Ginna was granted 50,000 shares (SEC Form 4)

      4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)

      3/18/25 4:16:42 PM ET
      $CRGX

    $CRGX
    SEC Filings

    See more
    • SEC Form 10-Q filed by CARGO Therapeutics Inc.

      10-Q - CARGO Therapeutics, Inc. (0001966494) (Filer)

      5/8/25 4:09:49 PM ET
      $CRGX
    • SEC Form DEFA14A filed by CARGO Therapeutics Inc.

      DEFA14A - CARGO Therapeutics, Inc. (0001966494) (Filer)

      4/29/25 4:13:07 PM ET
      $CRGX
    • SEC Form DEF 14A filed by CARGO Therapeutics Inc.

      DEF 14A - CARGO Therapeutics, Inc. (0001966494) (Filer)

      4/29/25 4:10:16 PM ET
      $CRGX

    $CRGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

      SC 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)

      11/14/24 5:45:26 PM ET
      $CRGX
    • Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

      SC 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)

      11/14/24 3:16:32 PM ET
      $CRGX
    • Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

      SC 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)

      11/14/24 1:22:39 PM ET
      $CRGX